E nwere ọtụtụ ụzọ e si agwọ ọrịa cancer prostate, na-adabere n'ọkwa ọrịa ahụ nọ na ya na otú ọ dịruru ike, nakwa n'otú onye ọrịa ahụ dị n'ozuzu ya na ihe ndị ọ chọrọ ime.
Ụfọdụ n'ime ọgwụgwọ ndị a na-ahụkarị gụnyere:
1. Nlekota na-arụsi ọrụ ike: Ụzọ a na-agụnye ilekọta ọrịa cancer nke ọma site n'inyocha ya na ime nnyocha mgbe nile, kama ịmalite ọgwụgwọ ozugbo.
O nwere ike ịdị mma maka ụmụ nwoke nwere ọrịa cancer prostate dị ala.
2. Ịwa ahụ: Ịwa ahụ bụ ịwa ahụ e ji ewepụ akwara prostate.
A pụrụ ime ya site n'ịwa ahụ́ n'ihu ọha ma ọ bụ site n'iji laparoscopically (iji obere ọnyá na ngwá ọrụ pụrụ iche) mee ya.
3. Ọgwụgwọ ụzarị ọkụ: Ọgwụgwọ a na-eji ụzarị ọkụ dị elu egbu mkpụrụ ndụ kansa.
A pụrụ inye ya n'èzí (site n'ụgbọala dị n'èzí ahụ) ma ọ bụ n'ime (site n'itinye ihe ndị e tinyere n'ebe dị nso n'ọrịa ahụ).
4. Ọgwụgwọ hormone: Ọgwụgwọ a na-ebelata ọkwa nke homonụ nwoke (androgens) n'ahụ, bụ́ nke pụrụ ime ka uto nke ọrịa cancer prostate belata ma ọ bụ kwụsị.
A pụrụ iji ya mee ihe nanị ya ma ọ bụ jikọta ya na ọgwụgwọ ndị ọzọ.
5. Chemotherapy: Ọgwụ ndị a na-eji egbu mkpụrụ ndụ cancer.
A pụrụ iji ya mee ihe maka ọrịa cancer prostate na- arịwanye elu nke gbasasịrị n" akụkụ ndị ọzọ nke ahụ .
6. Ọgwụ mgbochi ọrịa: Ọgwụ a na-enyere usoro mgbochi ọrịa aka ịlụso ọrịa cancer ọgụ.
Enwere ike iji ya maka ọrịa cancer prostate dị elu nke na- azaghị ọgwụgwọ ndị ọzọ.
7. Ọgwụgwọ e lekwasịrị anya: Ọgwụgwọ a na-elekwasị anya n'ahụ́ mkpụrụ ndụ ihe nketa ma ọ bụ protein ndị na-enyere mkpụrụ ndụ kansa aka itolite ma lanarị.
Enwere ike iji ya maka ọrịa cancer prostate dị elu nke na- azaghị ọgwụgwọ ndị ọzọ.
8. Cryotherapy: Ọgwụgwọ a na-eji oké oyi eme ihe iji kpoo ma gbuo mkpụrụ ndụ cancer.
A pụrụ iji ya mee ihe maka ọrịa cancer prostate dị n'oge ma ọ bụ maka ọrịa cancer nke laghachiri azụ mgbe a gwọchara ya.
9. High-intensity focused ultrasound (HIFU): Ọgwụgwọ a na-eji ebili mmiri ụda dị elu eme ihe iji kpoo ma bibie mkpụrụ ndụ cancer.
A pụrụ iji ya mee ihe maka ọrịa cancer prostate dị n'oge ma ọ bụ maka ọrịa cancer nke laghachiri azụ mgbe a gwọchara ya.
10. Na-eche nche: Ụzọ a na-agụnye ilekọta ọrịa cancer ahụ nke ọma site n'inyocha ya na ime nnyocha mgbe nile, ma ịghara ịmalite ọgwụgwọ ọ gwụla ma mgbaàmà ya apụta ma ọ bụ gbanwee.
Ọ pụrụ ịdị mma maka ndị ikom meworo agadi nwere ọrịa cancer prostate na-eto nwayọọ nwayọọ na ọnọdụ ahụ ike ndị ọzọ dị oké njọ.
Ọ dị mkpa ka gị na ndị nlekọta ahụ ike kwurịta ụzọ nile a pụrụ isi gwọọ gị iji chọpụta ihe kasị mma ị ga-eme n'ọnọdụ nke ọ bụla.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
Nkwupụta: ọgwụgwọ
A na-enye weebụsaịtị a maka ebumnuche agụmakwụkwọ na ozi naanị ma ọ bụghị inye ndụmọdụ ahụike ma ọ bụ ọrụ ọkachamara.
E kwesịghị iji ihe ọmụma e nyere mee ihe maka ịchọpụta ma ọ bụ ịgwọ nsogbu ahụ ike ma ọ bụ ọrịa, ndị na-achọ ndụmọdụ ahụike onwe ha kwesịrị ịgakwuru dọkịta nwere ikike.
Biko rịba ama na netwọkụ akwara nke na-emepụta azịza nye ajụjụ ndị ahụ, bụ ihe na-ezighi ezi mgbe ọ na-abịa na ọnụọgụ ọnụọgụ. Dịka ọmụmaatụ, ọnụọgụ ndị mmadụ chọpụtara na ọrịa akọwapụtara.
Na-achọkarị ndụmọdụ nke dọkịta gị ma ọ bụ onye na-ahụ maka ahụike ọzọ ruru eru banyere ọnọdụ ahụike. Elegharala ndụmọdụ ahụike ọkachamara anya ma ọ bụ na-egbu oge n'ịchọ ya n'ihi ihe ị gụrụ na weebụsaịtị a. Ọ bụrụ na i chere na ị nwere ike ịnweta mberede ahụike, kpọọ 911 ma ọ bụ gaa n'ọnụ ụlọ mberede kacha nso ozugbo. Enweghị mmekọrịta dọkịta na onye ọrịa na-emepụta site na weebụsaịtị a ma ọ bụ ojiji ya. Ma BioMedLib ma ndị ọrụ ya, ma onye ọ bụla na-enye aka na weebụsaịtị a, anaghị eme nkwupụta ọ bụla, kwupụta ma ọ bụ kwupụta, gbasara ozi enyere ebe a ma ọ bụ ojiji ya.
Nkwupụta: ikike nwebisiinka
Digital Millennium Copyright Act nke 1998, 17 U.S.C. § 512 (DMCA) na-enye ohere maka ndị nwe ikike nwebisiinka nke kwenyere na ihe na-apụta na ịntanetị na-emebi ikike ha n'okpuru iwu ikike nwebisiinka US.
Ọ bụrụ na ị kwenyere n'ezi okwukwe na ọdịnaya ma ọ bụ ihe ọ bụla enyere na njikọ nke weebụsaịtị anyị ma ọ bụ ọrụ na-emebi ikike nwebisiinka gị, gị (ma ọ bụ onye nnọchi anya gị) nwere ike iziga anyị ọkwa na-arịọ ka ewepụ ọdịnaya ma ọ bụ ihe, ma ọ bụ gbochie ịnweta ya.
A ghaghị izipu ọkwa n'akwụkwọ site na email (lee ngalaba "Kọntaktị" maka adreesị email) .
DMCA na-achọ ka ọkwa gị banyere mmebi iwu nwebisiinka na-ekwu na ọ gụnyere ozi ndị a: (1) nkọwa nke ọrụ nwebisiinka nke bụ isiokwu nke mmebi iwu a na-ekwu; (2) nkọwa nke ihe a na-ekwu na ọ na-emebi iwu na ozi zuru ezu iji mee ka anyị chọta ọdịnaya ahụ; (3) ozi kọntaktị maka gị, gụnyere adreesị gị, nọmba ekwentị na adreesị email; (4) nkwupụta site n'aka gị na ị nwere ezi okwukwe na ọdịnaya n'ụzọ a na-eme mkpesa na ọ bụghị ikike site n'aka onye nwe ikike, ma ọ bụ onye nnọchi anya ya, ma ọ bụ site na ọrụ iwu ọ bụla;
(5) nkwupụta site n'aka gị, nke ị bịanyere aka na ya n'okpuru ntaramahụhụ nke ịgba akaebe ụgha, na ozi dị na ọkwa ahụ ziri ezi na na ị nwere ikike iji mezuo ikike nwebisiinka nke a na-ekwu na emebi;
na (6) mbinye aka nkịtị ma ọ bụ nke elektrọnik nke onye nwe ikike ma ọ bụ onye e nyere ikike ime ihe n'aha onye nwe ikike.
Ọ bụrụ na i tinyeghị ozi niile dị n'elu, ọ nwere ike ime ka a na-egbu oge n'ịhazi mkpesa gị.
Mkparịta ụka
Biko zitere anyị email na ajụjụ ọ bụla / aro.
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
